Core Viewpoint - The Hong Kong and A-share markets are experiencing positive trends, with the medical device sector showing signs of recovery, particularly in the context of policy optimization and inventory reduction. MicroTech Medical (02235.HK) has reported significant revenue growth and a return to profitability, driven by strong CGM sales, overseas market expansion, and improved operational efficiency [1][12]. Group 1: Market Trends and Opportunities - The medical device sector is benefiting from favorable market conditions, with a bullish outlook for the industry as a whole [1]. - The global diabetes patient population is projected to exceed 589 million in 2024, with China leading in numbers, indicating a growing market for diabetes management solutions [4]. - Continuous Glucose Monitoring (CGM) technology is transforming blood sugar management, offering real-time data and improving patient experiences compared to traditional methods [5]. Group 2: Company Performance and Growth - MicroTech Medical's revenue for 2025 is expected to reach at least 650 million yuan, representing an approximate 88.1% year-on-year increase, with a net profit of over 38 million yuan [12]. - The company has seen robust growth in its core CGM product, with significant international market expansion contributing to its revenue increase [12]. - The reduction in sales and management expenses has improved profitability, marking a transition from a strategic loss phase to a profit-driven growth stage [12]. Group 3: Strategic Advantages - MicroTech Medical is uniquely positioned with a comprehensive product lineup, including both a patch insulin pump and a real-time CGM, providing a full spectrum solution for diabetes management [16]. - The company is exploring AI applications in CGM, enhancing personalized health management services through data analysis [17]. - The increasing share of overseas revenue demonstrates the company's global market capabilities, with potential for further growth in emerging markets [18]. Group 4: Market Valuation and Future Outlook - The recent performance forecast is expected to catalyze a revaluation of MicroTech Medical's stock, supported by its unique product offerings and global growth potential [20]. - Leading brokerages have expressed optimistic views on the company's future, with target prices indicating significant undervaluation compared to global peers [20].

集团于报告期间实现收入大幅增长，成功扭亏为盈，主要受益于：1)集团核心产品之一持续葡萄糖监测 系统收入持续强劲增长;2)海外市场拓展成效显著，LinX持续葡萄糖监测系统成功进入多个国家，国际 收入同比实现显著增长;3)精益管理持续深化，经营效率显著提升，集团销售费用和管理费用占收入比 例实现大幅下降。 微泰医疗-B(02235)发布公告，预计集团截至2025年12月31日年度的收入将不低于人民币6.50亿元，同比 增长约88.1%。预计集团2025年度实现归属于母公司所有者的净利润将不低于人民币3800万元，对比 2024年度的人民币-6310万元，增长人民币1.011亿元。 ...

格隆汇2月26日丨微泰医疗-B(02235.HK)发布公告，截至2025年12月31日年度("报告期间")，业绩预告情 况如下：1)预计集团报告期间的收入将不低于人民币6.50亿元，对比截至2024年12月31日止年度的人民 币3.456亿元，同比增长约88.1%。2)预计集团报告期间实现归属于母公司所有者的净利润将不低于人民 币3800万元，对比截至2024年12月31日止年度的人民币-6310万元，增长人民币1.011亿元。 集团于报告期间实现收入大幅增长，成功扭亏为盈，主要受益于：1)集团核心产品之一持续葡萄糖监测 系统收入持续强劲增长；2)海外市场拓展成效显著，LinX持续葡萄糖监测系统成功进入多个国家，国际 收入同比实现显着增长；及3)精益管理持续深化，经营效率显著提升，集团销售费用和管理费用占收入 比例实现大幅下降。 ...

集团于报告期间实现收入大幅增长，成功扭亏为盈，主要受益于：1)集团核心产品之一持续葡萄糖监测 系统收入持续强劲增长;2)海外市场拓展成效显著，LinX持续葡萄糖监测系统成功进入多个国家，国际 收入同比实现显著增长;3)精益管理持续深化，经营效率显著提升，集团销售费用和管理费用占收入比 例实现大幅下降。 智通财经APP讯，微泰医疗-B(02235)发布公告，预计集团截至2025年12月31日年度的收入将不低于人民 币6.50亿元，同比增长约88.1%。预计集团2025年度实现归属于母公司所有者的净利润将不低于人民币 3800万元，对比2024年度的人民币-6310万元，增长人民币1.011亿元。 ...

Core Viewpoints - The company announced that its LinX continuous glucose monitoring (CGM) system has recently received market approval in Brazil, further strengthening its international expansion strategy [1] - The CGM product is expected to continue its growth trend in the domestic market through both online and offline channels, while overseas markets show significant potential for revenue growth due to a low revenue base and increasing market share [1][3] - The company reported a net loss of only 2.29 million yuan in the first half of 2025, nearing breakeven, with expectations of achieving profitability by 2026 [1][3] Event Summary - On December 23, 2025, the company announced that its LinX CGM system received market approval in Brazil for both adults and children, enhancing its market presence in Latin America [1] Market Performance - The company reported a 218% increase in GMV during the "Double Eleven" shopping festival, with the second-generation CGM device's shipment volume increasing by 622.8% and new user numbers rising by 300% [2] - The company ranked first in sales on major e-commerce platforms, indicating effective brand promotion [2] R&D Progress - The company is making steady progress in its R&D pipeline, with clinical trials for the AiDEX CGM system for pregnant women completed and the Equil insulin pump system's clinical trial enrollment in Europe finished [2] - The company is exploring AI applications in CGM through internal team formation and collaborations with leading research institutions, aiming to innovate diabetes management [2] Revenue and Profit Outlook - The company expects continued high revenue growth in 2026, with a projected revenue of 5.31 billion yuan in 2025, representing a year-on-year growth of 53.78% [3] - The company anticipates achieving breakeven in 2025 and profitability in 2026, supported by stable gross margins and cost optimization measures [3]

Core Viewpoint - The company, Microtech Medical-B (02235), has received approval for its LinX continuous glucose monitoring system in Brazil, which is expected to enhance its market presence in Latin America and drive revenue growth [1]. Group 1: Company Performance - As of December 24, 2025, the stock closed at 7.68 yuan, reflecting a 0.52% increase from the previous trading day [1]. - The stock's 52-week high is 9.17 yuan, while the low is 4.0 yuan [1]. Group 2: Market Opportunity - Brazil is identified as a core market in Latin America, with approximately 16.62 million diabetes patients aged 20-79, representing a prevalence rate of 10.7%, ranking sixth globally [1]. - Diabetes-related expenditures in Brazil are projected to reach approximately $45.1 billion in 2024, making it the third highest globally [1]. Group 3: Strategic Focus - The company aims to continue focusing on technological innovation and global development in the diabetes monitoring, treatment, and management sectors [1].

Group 1: Copper Price Surge - Copper prices have reached a historic high, surpassing $12,000 per ton, driven by significant mine shutdowns and trade disruptions caused by U.S. tariffs [1] - The London Metal Exchange's copper futures peaked at $12,044 per ton, reflecting a cumulative increase of approximately 37% this year [1] - The potential imposition of tariffs on copper by President Trump has been a key factor in driving prices up, with U.S. imports rising sharply [1] Group 2: Supply Chain Disruptions - Severe disruptions in the supply chain due to mine shutdowns across the Americas, Africa, and Asia are raising concerns about a significant copper market deficit [1] - Deutsche Bank has warned that the production of the world's largest mining companies is expected to decline by 3% this year, with further declines anticipated by 2026 [1] Group 3: Precious Metals Market - The bull market for precious metals continues, with gold, silver, copper, and platinum all reaching new highs [2] - COMEX gold futures rose by $45.60, or 1.02%, to $4,515.0 per ounce, while COMEX silver futures increased by $3.045, or 4.44%, to $71.61 per ounce [2]

Core Viewpoint - MicroTech Medical-B (02235.HK) has received approval for its LinX continuous glucose monitoring system in Brazil, targeting both adults and children for dynamic blood glucose monitoring [1] Market Potential - Brazil is identified as a core market in Latin America with significant potential, housing approximately 16.62 million diabetes patients aged 20-79, representing a prevalence rate of 10.7%, ranking sixth globally [1] - Diabetes-related expenditures in Brazil are projected to reach approximately $45.1 billion in 2024, making it the third highest globally, following the United States and China [1] Strategic Implications - The approval of the LinX continuous glucose monitoring system in Brazil is expected to significantly enhance the company's market presence in Latin America, laying a solid foundation for the scaling of international operations and revenue growth [1] - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [1]

Core Viewpoint - MicroTech Medical-B (02235) has received approval for its LinX continuous glucose monitoring system in Brazil, which is applicable for both adults and children, significantly enhancing the company's market presence in Latin America [1] Group 1: Product Approval - The LinX continuous glucose monitoring system has been approved for sale in Brazil, marking a key milestone for the company [1] - This approval is expected to strengthen the company's market positioning in Latin America [1] Group 2: Business Expansion - The approval lays a solid foundation for the company's international business expansion and revenue growth [1] - The company will continue to focus on the global development of diabetes monitoring, treatment, and management [1] Group 3: Innovation Focus - The company aims to drive ongoing technological and product innovation in the relevant fields [1]

Core Viewpoint - The company has received approval for its LinX continuous glucose monitoring system in Brazil, which will significantly enhance its market presence in Latin America and support international business expansion and revenue growth [1] Group 1: Product Approval - The LinX continuous glucose monitoring system is now approved for use in both adults and children in Brazil [1] Group 2: Market Impact - The approval is expected to strengthen the company's market positioning in Latin America, laying a solid foundation for scaling international operations and increasing revenue [1] Group 3: Future Focus - The company will continue to focus on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [1]